Table 1.

Analysis of the potential synergy of the combined treatments of different AML cell lines with Setanaxib and with different cytotoxic drugs. 32D FLT3-ITD, MV4-11, or MOLM13 cells were subjected to drug treatments. Experimental conditions for cell treatments were as in Figure 2. Setanaxib was applied at 1, 3, 10 or 30 µM, cytarabine at 100 or 500 nM, daunorubicin at 20 or 30 nM, and midostaurin at 10 or 20 nM. The proliferation/viability of the cells was assessed by Cell Titer Blue assay after 72 h of treatments. Apoptosis rates were measured by FACS analysis after 48 h of treatments. The CI values were calculated with the Chou method using the software Calcusyn. A CI of <1 indicates synergism (<0.1 very strong synergism (+++++), 0.1 to 0.3 strong synergism (++++), 0.3 to 0.7 synergism (+++), 0.7 to 0.85, moderate synergism (++), 0.85 to 0.90, low synergism (+), and 0.90 to 1.1, nearly additive (±). Three independent experiments (in triplicate) were conducted.

Proliferation/Viability (Cell Titer Blue)
	Chemotherapy drugs	32D FLT3-ITD	MV4-11	MOLM13
Setanaxib	Cytarabine	+++	±	±
	Daunorubicin	+++++	+++	+++
	Midostaurin	++++	+++	++
Apoptosis (Annexin V + 7-AAD)
	Chemotherapy drugs	32D FLT3-ITD	MV4-11
Setanaxib	Cytarabine	+++	±
	Daunorubicin	+++++	+
	Midostaurin	++++	++